Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Darrick Carter

Showing results (81-90 of 101) with videos related to

Pageof 11
Sort By:
Scientific Reports|July 2, 2025
Potential biomarker and composite efficacy readout for human clinical trials of schistosomiasis vaccine in AfricaDesalegn W Kifle, Aravindan Kalyanasundaram, Adebayo J Molehin, et al.
Clinical & Translational Immunology|December 20, 2016
A structure-function approach to optimizing TLR4 ligands for human vaccinesDarrick Carter, Christopher B Fox, Tracey A Day, et al.
Parasitology Research|April 15, 2014
Longevity of Sm-p80-specific antibody responses following vaccination with Sm-p80 vaccine in mice and baboons and transplacental transfer of Sm-p80-specific antibodies in a baboonWeidong Zhang, Gul Ahmad, Loc Le, et al.
Clinical and Vaccine Immunology : CVI|December 18, 2009
Rational design and evaluation of a multiepitope chimeric fusion protein with the potential for leprosy diagnosisMalcolm S Duthie, Marah N Hay, Cecile Z Morales, et al.
Clinical and Vaccine Immunology : CVI|August 22, 2008
Selection of antigens and development of prototype tests for point-of-care leprosy diagnosisMalcolm S Duthie, Greg C Ireton, Ganga V Kanaujia, et al.
NPJ Vaccines|November 24, 2025
Safety and immunogenicity of the Sm-p80 GLA-SE schistosomiasis vaccineLisa A Jackson, Rhea N Coler, Gregory A Deye, et al.
Vaccine|February 26, 2011
A synthetic TLR4 agonist formulated in an emulsion enhances humoral and Type 1 cellular immune responses against GMZ2--a GLURP-MSP3 fusion protein malaria vaccine candidateSusana Lousada-Dietrich, Prajakta S Jogdand, Søren Jepsen, et al.
NPJ Vaccines|December 22, 2017
Protein nanovaccine confers robust immunity against <i>Toxoplasma</i>Kamal El Bissati, Ying Zhou, Sara Maria Paulillo, et al.
NPJ Vaccines|March 14, 2025
A functional enzymatic assay as potential readout for a clinical trial of a schistosomiasis vaccineDesalegn W Kifle, Mumtaz Y Balkhi, Yasuko Ono, et al.
NPJ Vaccines|February 16, 2023
Semi-synthetic terpenoids with differential adjuvant properties as sustainable replacements for shark squalene in vaccine emulsionsKarl J Fisher, Robert Kinsey, Raodoh Mohamath, et al.
Pageof 11

Showing results (81-90 of 101) with videos related to

Sort By:
Pageof 11
Scientific Reports|July 2, 2025
Potential biomarker and composite efficacy readout for human clinical trials of schistosomiasis vaccine in AfricaDesalegn W Kifle, Aravindan Kalyanasundaram, Adebayo J Molehin, et al.
Clinical & Translational Immunology|December 20, 2016
A structure-function approach to optimizing TLR4 ligands for human vaccinesDarrick Carter, Christopher B Fox, Tracey A Day, et al.
Parasitology Research|April 15, 2014
Longevity of Sm-p80-specific antibody responses following vaccination with Sm-p80 vaccine in mice and baboons and transplacental transfer of Sm-p80-specific antibodies in a baboonWeidong Zhang, Gul Ahmad, Loc Le, et al.
Clinical and Vaccine Immunology : CVI|December 18, 2009
Rational design and evaluation of a multiepitope chimeric fusion protein with the potential for leprosy diagnosisMalcolm S Duthie, Marah N Hay, Cecile Z Morales, et al.
Clinical and Vaccine Immunology : CVI|August 22, 2008
Selection of antigens and development of prototype tests for point-of-care leprosy diagnosisMalcolm S Duthie, Greg C Ireton, Ganga V Kanaujia, et al.
NPJ Vaccines|November 24, 2025
Safety and immunogenicity of the Sm-p80 GLA-SE schistosomiasis vaccineLisa A Jackson, Rhea N Coler, Gregory A Deye, et al.
Vaccine|February 26, 2011
A synthetic TLR4 agonist formulated in an emulsion enhances humoral and Type 1 cellular immune responses against GMZ2--a GLURP-MSP3 fusion protein malaria vaccine candidateSusana Lousada-Dietrich, Prajakta S Jogdand, Søren Jepsen, et al.
NPJ Vaccines|December 22, 2017
Protein nanovaccine confers robust immunity against <i>Toxoplasma</i>Kamal El Bissati, Ying Zhou, Sara Maria Paulillo, et al.
NPJ Vaccines|March 14, 2025
A functional enzymatic assay as potential readout for a clinical trial of a schistosomiasis vaccineDesalegn W Kifle, Mumtaz Y Balkhi, Yasuko Ono, et al.
NPJ Vaccines|February 16, 2023
Semi-synthetic terpenoids with differential adjuvant properties as sustainable replacements for shark squalene in vaccine emulsionsKarl J Fisher, Robert Kinsey, Raodoh Mohamath, et al.
Pageof 11